MCID: CTN004
MIFTS: 45

Cutaneous Fibrous Histiocytoma

Categories: Rare diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Cutaneous Fibrous Histiocytoma

MalaCards integrated aliases for Cutaneous Fibrous Histiocytoma:

Name: Cutaneous Fibrous Histiocytoma 12 49 14 69
Dermatofibroma 12 72 49 51
Fibrohistiocytic Tumor 12 69
Benign Cutaneous Fibrous Histiocytoma 12
Dermatofibroma, No Icd-O Subtype 12
Fibrous Histiocytoma of Skin 12
Sclerosing Angioma of Skin 12
Fibrohistiocytic Neoplasm 12
Fibrous Xanthoma of Skin 12
Pleomorphic Fibroma 12
Dermatofibroma Nos 12
Sclerosing Angioma 12

Classifications:



Summaries for Cutaneous Fibrous Histiocytoma

NIH Rare Diseases : 49 Dermatofibroma is a common benign skin nodule. It frequently develops on the extremities (most often the lower legs). Although it is generally not associated with any signs or symptoms, some affected people may experience itching and/or tenderness. Dermatofibromas are found in people of all ages and ethnicity and are more commonly diagnosed in women than men. The underlying cause of dermatofibroma is currently unknown. Treatment is generally not required, but if symptoms are present, the lesion can be surgically removed. Last updated: 3/19/2017

MalaCards based summary : Cutaneous Fibrous Histiocytoma, also known as dermatofibroma, is related to myxofibrosarcoma and fibrous histiocytoma. An important gene associated with Cutaneous Fibrous Histiocytoma is F13A1 (Coagulation Factor XIII A Chain), and among its related pathways/superpathways are Cytoskeletal Signaling and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and lung, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 72 Benign fibrous histiocytomas (also known as dermal dendrocytoma,dermatofibroma,fibrous... more...

Related Diseases for Cutaneous Fibrous Histiocytoma

Diseases related to Cutaneous Fibrous Histiocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Related Disease Score Top Affiliating Genes
1 myxofibrosarcoma 30.2 DES S100B
2 fibrous histiocytoma 29.7 ACTC1 CD163 DES F13A1 VIM
3 cutaneous leiomyosarcoma 29.7 ACTC1 DES VIM
4 pleomorphic liposarcoma 29.2 ACTC1 DES S100B VIM
5 leiomyosarcoma 29.2 ACTC1 DES S100B VIM
6 dermatofibrosarcoma protuberans 27.4 ACTC1 CD163 DES F13A1 MMP11 PDGFB
7 histiocytoma 11.6
8 malignant skin fibrous histiocytoma 11.4
9 sclerosing hemangioma 11.2
10 undifferentiated pleomorphic sarcoma 11.0
11 skin glomus tumor 10.4 DES VIM
12 infantile digital fibromatosis 10.4 DES VIM
13 multicentric reticulohistiocytosis 10.4 F13A1 VIM
14 generalized eruptive histiocytosis 10.4 F13A1 S100B
15 myofibroma 10.4 DES F13A1
16 lymphangiomatosis 10.4 DES VIM
17 primitive neuroectodermal tumor of the cervix uteri 10.4 DES VIM
18 granuloma annulare 10.4 F13A1 VIM
19 epulis 10.4 DES VIM
20 biphasic synovial sarcoma 10.4 DES VIM
21 malignant triton tumor 10.4 DES S100B
22 hydromyelia 10.4 S100B VIM
23 primary hepatic neuroendocrine carcinoma 10.3 S100B VIM
24 chordoid meningioma 10.3 S100B VIM
25 mesenchymal chondrosarcoma 10.3 DES VIM
26 extraskeletal ewing sarcoma 10.3 DES VIM
27 eccrine porocarcinoma 10.3 S100B VIM
28 myxopapillary ependymoma 10.3 S100B VIM
29 monophasic synovial sarcoma 10.3 S100B VIM
30 anaplastic ependymoma 10.3 S100B VIM
31 benign mesothelioma 10.3 DES VIM
32 perineurioma 10.3 S100B VIM
33 odontogenic myxoma 10.3 S100B VIM
34 cerebral primitive neuroectodermal tumor 10.2 S100B VIM
35 progressive nodular histiocytosis 10.2 ACTC1 F13A1
36 hidradenocarcinoma 10.2 S100B VIM
37 scleromyxedema 10.2 ACTC1 F13A1
38 ovarian fibrothecoma 10.2 ACTC1 DES
39 papillary adenocarcinoma 10.2 S100B VIM
40 lymphangiectasis 10.2 ACTC1 VIM
41 focal hand dystonia 10.2 PDGFB VIM
42 glomangiomyoma 10.2 ACTC1 VIM
43 intravascular papillary endothelial hyperplasia 10.2 ACTC1 VIM
44 osteochondroma 10.2 S100B VIM
45 rosai-dorfman disease 10.2 CD163 S100B
46 optic nerve glioma 10.2 S100B VIM
47 pulmonary vein stenosis 10.2 ACTC1 DES
48 cystic nephroma 10.2 ACTC1 DES
49 malignant giant cell tumor of soft parts 10.2 ACTC1 S100B
50 ependymoma 10.2 S100B VIM

Graphical network of the top 20 diseases related to Cutaneous Fibrous Histiocytoma:



Diseases related to Cutaneous Fibrous Histiocytoma

Symptoms & Phenotypes for Cutaneous Fibrous Histiocytoma

MGI Mouse Phenotypes related to Cutaneous Fibrous Histiocytoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.7 ACTC1 CD163 DES F13A1 MMP11 PDGFB
2 homeostasis/metabolism MP:0005376 9.56 ACTC1 CD163 DES F13A1 MMP11 PDGFB
3 muscle MP:0005369 9.02 ACTC1 CD163 DES PDGFB VIM

Drugs & Therapeutics for Cutaneous Fibrous Histiocytoma

Drugs for Cutaneous Fibrous Histiocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
8
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
9
Epirubicin Approved Phase 3 56420-45-2 41867
10
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
14 Alkylating Agents Phase 3,Phase 2,Phase 1
15 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
16 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
17 Anti-Infective Agents Phase 3,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
19 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
20 Etoposide phosphate Phase 3,Phase 2
21 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
22 Antimitotic Agents Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Antirheumatic Agents Phase 3,Phase 2,Phase 1
25
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
26
Indinavir Approved Phase 2 150378-17-9 5362440
27
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
28
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
29
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
30
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
31
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
32
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
33
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
34
Bevacizumab Approved, Investigational Phase 2 216974-75-3
35
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 46835353 6436030 5284616
36
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
37
nivolumab Approved Phase 2,Phase 1 946414-94-4
38
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
39
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
40
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
41
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
42
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
43
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
45
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
46
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
47
Camptothecin Experimental Phase 2 7689-03-4
48 Exatecan Investigational Phase 2 171335-80-1
49
Saracatinib Investigational Phase 2 379231-04-6
50 Soblidotin Investigational Phase 2 149606-27-9

Interventional clinical trials:

(show top 50) (show all 67)

# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
5 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
11 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
12 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
13 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
14 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
15 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
16 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
17 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
18 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
19 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
20 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
21 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
22 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
23 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
24 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
26 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
27 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
28 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
29 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
30 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
31 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
32 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
33 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
34 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
35 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
36 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
37 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
38 Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2 Nivolumab;Ipilimumab
39 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
40 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Recruiting NCT02500797 Phase 2
41 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
42 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
43 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
44 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
45 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
46 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Active, not recruiting NCT01962103 Phase 1, Phase 2 nab-paclitaxel
47 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Suspended NCT02923778 Phase 2
48 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
49 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
50 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib

Search NIH Clinical Center for Cutaneous Fibrous Histiocytoma

Genetic Tests for Cutaneous Fibrous Histiocytoma

Anatomical Context for Cutaneous Fibrous Histiocytoma

MalaCards organs/tissues related to Cutaneous Fibrous Histiocytoma:

38
Skin, Bone, Lung, Endothelial, Liver, Testis, Brain

Publications for Cutaneous Fibrous Histiocytoma

Articles related to Cutaneous Fibrous Histiocytoma:

(show all 15)
# Title Authors Year
1
Metastasizing "benign" cutaneous fibrous histiocytoma: a clinicopathologic analysis of 16 cases. ( 23426120 )
2013
2
Atypical cutaneous fibrous histiocytoma: an unusual and misleading variant of fibrous histiocytoma. ( 22937387 )
2011
3
A study of monocytic and dendritic cell markers in benign cutaneous fibrous histiocytoma (dermatofibroma). ( 18462367 )
2008
4
A unique biphasic variant of cutaneous fibrous histiocytoma with a storiform pattern and intralesional pigmented melanocytes: "storiform melano-fibrous histiocytoma". ( 18474466 )
2008
5
The value of immunohistochemistry in atypical cutaneous fibrous histiocytoma. ( 15365367 )
2004
6
Clonal analysis of cutaneous fibrous histiocytoma (dermatofibroma). ( 12139632 )
2002
7
Aneurysmal fibrous histiocytoma: an unusual variant of cutaneous fibrous histiocytoma. ( 10461644 )
1999
8
Recurring atypical ("pseudosarcomatous") cutaneous fibrous histiocytoma. ( 9649666 )
1998
9
Cutaneous fibrous histiocytoma. ( 9158319 )
1997
10
Cutaneous fibrous histiocytoma with osteoclast-like giant cells. ( 8863988 )
1996
11
Cellular benign fibrous histiocytoma. Clinicopathologic analysis of 74 cases of a distinctive variant of cutaneous fibrous histiocytoma with frequent recurrence. ( 8017561 )
1994
12
Palisading cutaneous fibrous histiocytoma. An immunohistochemical study demonstrating differentiation from dermal dendrocytes. ( 8311187 )
1993
13
Atypical, cutaneous fibrous histiocytoma with early metastasis. ( 3012378 )
1986
14
Atypical cutaneous fibrous histiocytoma. ( 3028197 )
1986
15
Palisading cutaneous fibrous histiocytoma. ( 3029199 )
1986

Variations for Cutaneous Fibrous Histiocytoma

Cosmic variations for Cutaneous Fibrous Histiocytoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM231651 PREX2 skin,leg,malignant melanoma,nodular c.2323C>T p.P775S 7
2 COSM231662 PREX2 skin,leg,malignant melanoma,nodular c.4127C>T p.A1376V 7
3 COSM580 NRAS skin,leg,malignant melanoma,nodular c.181C>A p.Q61K 7
4 COSM586 NRAS skin,leg,malignant melanoma,nodular c.183A>C p.Q61H 7
5 COSM581 NRAS skin,leg,malignant melanoma,nodular c.181C>G p.Q61E 7
6 COSM584 NRAS skin,leg,malignant melanoma,nodular c.182A>G p.Q61R 7
7 COSM25914 MLH1 skin,leg,malignant melanoma,nodular c.1732-1G>A p.? 7
8 COSM476 BRAF skin,leg,malignant melanoma,nodular c.1799T>A p.V600E 7
9 COSM231652 skin,leg,malignant melanoma,nodular c.2323C>T p.P775S 7

Expression for Cutaneous Fibrous Histiocytoma

Search GEO for disease gene expression data for Cutaneous Fibrous Histiocytoma.

Pathways for Cutaneous Fibrous Histiocytoma

Pathways related to Cutaneous Fibrous Histiocytoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.92 ACTC1 DES VIM
2 11.03 PDGFB S100B VIM
3
Show member pathways
10.81 DES VIM
4 10.66 ACTC1 DES VIM

GO Terms for Cutaneous Fibrous Histiocytoma

Cellular components related to Cutaneous Fibrous Histiocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 8.8 MMP11 PDGFB VIM

Biological processes related to Cutaneous Fibrous Histiocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament organization GO:0045109 8.96 DES VIM
2 muscle filament sliding GO:0030049 8.8 ACTC1 DES VIM

Sources for Cutaneous Fibrous Histiocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....